Aeglea BioTherapeutics
treatment resulted in dose dependent response and statistically significant lowering of in mouse model | Aeglea BioTherapeutics
Company
Deck Type
Sector
Industry
Deck date
March 2023
Slide
12 of 39
Similar slides by Aeglea BioTherapeutics
See diffirences between slides (animation)
Investor Presentation
May 2023
treatment resulted in dose dependent response and statistically significant lowering of in mouse model | Aeglea BioTherapeutics
Investor Presentation
April 2023
treatment resulted in dose dependent response and statistically significant lowering of in mouse model | Aeglea BioTherapeutics
Related slides by other companies
DICE Therapeutics
Investor Presentation
March 2023
demonstrated a dose dependent increase in serum a to levels comparable to dice | DICE Therapeutics
Arbutus Biopharma
Results
November 2022
demonstrates target engagement in cells in a mouse model | Arbutus Biopharma
NeuroBo Pharmaceuticals
Investor Presentation
December 2023
ongoing phase a in mash | NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals
Investor Presentation
January 2024
ongoing phase a in mash | NeuroBo Pharmaceuticals
Other recent decks by Aeglea BioTherapeutics
See all presentations (14 decks)
Investor Presentation
October 2023
Investor Presentation
October 2023
Investor Presentation
September 2023
Investor Presentation
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io